Interferon Neuanfang????????? - 500 Beiträge pro Seite
eröffnet am 09.02.04 18:18:43 von
neuester Beitrag 03.03.04 19:11:15 von
neuester Beitrag 03.03.04 19:11:15 von
Beiträge: 35
ID: 818.397
ID: 818.397
Aufrufe heute: 0
Gesamt: 1.646
Gesamt: 1.646
Aktive User: 0
Top-Diskussionen
Titel | letzter Beitrag | Aufrufe |
---|---|---|
heute 16:23 | 3563 | |
heute 15:47 | 3268 | |
vor 1 Stunde | 1811 | |
vor 50 Minuten | 1620 | |
vor 6 Minuten | 1483 | |
vor 1 Stunde | 1402 | |
vor 56 Minuten | 1381 | |
vor 56 Minuten | 1288 |
Meistdiskutierte Wertpapiere
Platz | vorher | Wertpapier | Kurs | Perf. % | Anzahl | ||
---|---|---|---|---|---|---|---|
1. | 1. | 18.001,60 | +0,59 | 240 | |||
2. | 2. | 168,20 | +0,08 | 87 | |||
3. | 3. | 9,7000 | +12,27 | 75 | |||
4. | 14. | 6,1400 | -1,35 | 69 | |||
5. | 11. | 0,1865 | 0,00 | 52 | |||
6. | 7. | 0,8750 | -12,50 | 47 | |||
7. | 12. | 0,1561 | +2,97 | 38 | |||
8. | 6. | 2.302,50 | 0,00 | 36 |
Jetzt ist die Zeit um einzusteigen
ISI`S BOARD OF DIRECTORS RECOMMENDS A VOTE "FOR" THE APPROVAL OF THE ASSET
SALE.
Security Ownership of Certain Beneficial Owners and Management of ISI
The following table sets forth certain information regarding the beneficial ownership of the common stock of ISI as of September 30, 2003 by (i) each stockholder who is known by ISI to own beneficially 5% percent or more of the common stock of ISI; (ii) each of ISI`s directors; (iii) each of ISI`s executive officers; and (iv) all of ISI`s directors and executive officers as a group.
Except as otherwise noted, the address of each person listed in the table is c/o Interferon Sciences, Inc., 783 Jersey Avenue, New Brunswick, New Jersey 08901. Unless otherwise indicated, to ISI`s knowledge, all persons listed below have sole voting and investment power with respect to their shares of ISI`s common stock, except to the extent authority is shared by spouses under applicable law. Beneficial ownership is determined in accordance with the rules of the Securities and Exchange Commission and includes voting and investment power with respect to shares. Applicable percentage ownership is based on 37,339,286 shares of common stock outstanding as of September 30, 2003 together with options that are currently exercisable or exercisable within 60 days of September 30, 2003. In computing the number and percentage of shares beneficially owned by a person, shares of common stock subject to options currently exercisable, or exercisable within 60 days of September, 30, 2003 are counted as outstanding, while these shares are not counted as outstanding for computing the percentage ownership of any other person.
Of Total Number
Of Shares
Beneficially
Total Number Percent of Owned
of Shares Common Shares which
Beneficially Stock May be Acquired
Name Owned Owned Within 60 Days
---- -------------- ----------- -----------------
Margie Chassman 32,666,699(1) 42.9% (1) 16,666,667 (1)
445 West 23rd Street
New York, NY 10011
Metacine, Inc.
46 Bouvant Drive
Princeton, NJ 08540 2,714,000 7.2% 0
Samuel H. Ronel, Ph.D. 373,018(2) 1.0% 312,265
Lawrence M. Gordon 591,485(3) 1.6% 509,005
Stanley G. Schutzbank, Ph.D. 558,243(4) 1.5% 484,875
Sheldon L. Glashow 12,250(5) * 12,250
Directors and Executive
Officers as a Group
(4 persons) 1,534,996(6) 4.1% 1,318,395
----------------
* The number of shares owned is less than one percent of the outstanding shares
of Common Stock.
(1) Includes (i) 1,666,667 shares that may be acquired upon the exercise of
warrants, exercisable, commencing until April 2005, at a price of $1.50 per
share, and (ii) 15,000,000 shares that may be acquired upon the exercise of
warrants, exercisable, commencing until March 2008, at a price of $.01 per
share. This amount would increase to approximately 60.5% if Ms. Chassman
exercised all of her warrants.
(2) Includes 312,263 shares that may be acquired at a price of $.25 per share
upon the exercise of stock options until December 31, 2003.
(3) Includes 509,005 shares that may be acquired at a price of $.25 per share
upon the exercise of stock options until December 31, 2003.
(4) Includes 484,875 shares that may be acquired at a price of $.25 per share
upon the exercise of stock options until December 31, 2003.
(5) Includes 12,250 shares that may be acquired at a price of $.25 per share
upon the exercise of stock options until December 31, 2003.
(6) Includes 1,318,395 shares that may be acquired at a price of $.25 per share
upon the exercise of stock options until December 31, 2003.
SALE.
Security Ownership of Certain Beneficial Owners and Management of ISI
The following table sets forth certain information regarding the beneficial ownership of the common stock of ISI as of September 30, 2003 by (i) each stockholder who is known by ISI to own beneficially 5% percent or more of the common stock of ISI; (ii) each of ISI`s directors; (iii) each of ISI`s executive officers; and (iv) all of ISI`s directors and executive officers as a group.
Except as otherwise noted, the address of each person listed in the table is c/o Interferon Sciences, Inc., 783 Jersey Avenue, New Brunswick, New Jersey 08901. Unless otherwise indicated, to ISI`s knowledge, all persons listed below have sole voting and investment power with respect to their shares of ISI`s common stock, except to the extent authority is shared by spouses under applicable law. Beneficial ownership is determined in accordance with the rules of the Securities and Exchange Commission and includes voting and investment power with respect to shares. Applicable percentage ownership is based on 37,339,286 shares of common stock outstanding as of September 30, 2003 together with options that are currently exercisable or exercisable within 60 days of September 30, 2003. In computing the number and percentage of shares beneficially owned by a person, shares of common stock subject to options currently exercisable, or exercisable within 60 days of September, 30, 2003 are counted as outstanding, while these shares are not counted as outstanding for computing the percentage ownership of any other person.
Of Total Number
Of Shares
Beneficially
Total Number Percent of Owned
of Shares Common Shares which
Beneficially Stock May be Acquired
Name Owned Owned Within 60 Days
---- -------------- ----------- -----------------
Margie Chassman 32,666,699(1) 42.9% (1) 16,666,667 (1)
445 West 23rd Street
New York, NY 10011
Metacine, Inc.
46 Bouvant Drive
Princeton, NJ 08540 2,714,000 7.2% 0
Samuel H. Ronel, Ph.D. 373,018(2) 1.0% 312,265
Lawrence M. Gordon 591,485(3) 1.6% 509,005
Stanley G. Schutzbank, Ph.D. 558,243(4) 1.5% 484,875
Sheldon L. Glashow 12,250(5) * 12,250
Directors and Executive
Officers as a Group
(4 persons) 1,534,996(6) 4.1% 1,318,395
----------------
* The number of shares owned is less than one percent of the outstanding shares
of Common Stock.
(1) Includes (i) 1,666,667 shares that may be acquired upon the exercise of
warrants, exercisable, commencing until April 2005, at a price of $1.50 per
share, and (ii) 15,000,000 shares that may be acquired upon the exercise of
warrants, exercisable, commencing until March 2008, at a price of $.01 per
share. This amount would increase to approximately 60.5% if Ms. Chassman
exercised all of her warrants.
(2) Includes 312,263 shares that may be acquired at a price of $.25 per share
upon the exercise of stock options until December 31, 2003.
(3) Includes 509,005 shares that may be acquired at a price of $.25 per share
upon the exercise of stock options until December 31, 2003.
(4) Includes 484,875 shares that may be acquired at a price of $.25 per share
upon the exercise of stock options until December 31, 2003.
(5) Includes 12,250 shares that may be acquired at a price of $.25 per share
upon the exercise of stock options until December 31, 2003.
(6) Includes 1,318,395 shares that may be acquired at a price of $.25 per share
upon the exercise of stock options until December 31, 2003.
Business of ISI Overview
On March 11, 2003, ISI entered into the Inventory Agreement with HEB pursuant to which ISI sold HEB all of its inventory related to ALFERON N Injection and granted HEB a three year license to sell ALFERON N Injection in the United States. In addition, on March 11, 2003 substantially all of ISI`s employees became employees of HEB. ISI also entered into the Asset Purchase Agreement pursuant to which ISI has agreed to sell its property, plant, furniture, equipment, all customer lists, computer files, data and software, books and records, manufacturing records and procedures, approval processes and approvals with and by the U.S. Food and Drug Administration and all other property, patents, trademarks, and rights of every kind and nature owned or held by ISI relating to natural alpha interferon, its production, manufacture and sale. Upon completion of the Asset Purchase Agreement, ISI will not be involved in the natural alpha interferon business and will not have a manufacturing and research facility. Therefore, ISI`s remaining assets will consist of cash, 586,056 shares of HEB Common Stock (consisting of 99,028 shares currently held by ISI and an additional 487,028 shares of HEB Common Stock to be received upon completion of the Asset Purchase Agreement), a royalty from HEB equal to 6% of sales of products containing natural alpha interferon, a note receivable and a warrant to purchase shares of Amphioxus Cell Technologies, Inc. ("ACT"). ISI does not intend to distribute the HEB Common Stock to the ISI shareholders and has entered into a non-binding Letter of Intent to acquire ACT.
ACT Letter of Intent
On October 17, 2003, ISI and ACT entered into a non-binding letter of intent pursuant to which ISI (or a wholly owned subsidiary of ISI) will acquire ACT. The shareholders of ACT will receive preferred stock (the "ACT Preferred Stock") of ISI, convertible into a number of common shares of ISI equal to 75% of the fully diluted capitalization of ISI. The ACT Preferred Stock will be convertible at the option of the holder at any time, and subject to mandatory conversion if, prior to the date which is two years after the merger, the sum of the proceeds received from (i) the sale of the assets of ISI at the date of merger, and (ii) common equity capital raised at a pre-money valuation in excess of $10 million, exceed $2.5 million.
Certain debt (the "ACT Debt") aggregating approximately $2.9 million that is currently owed to shareholders of ACT will continue as secured non-interest bearing debt of ISI. The ACT Debt will be non-interest bearing and repayable by ISI on the fourth anniversary of the date of the merger, subject to accelerated payment of 25% of the net after tax profits of ACT over $1 million on a cumulative basis. The ACT Debt shall be fully payable upon a change of control of ISI (excluding the transactions whereby the ACT stockholders convert the ACT Preferred Stock). In addition, the ACT Debt shall also be repaid to the extent of the net proceeds from the sale of any equity securities of ISI exceeding $8 million. In addition, certain additional debt aggregating approximately $200,000 owed to a shareholder of ACT will be repayable on the fifth anniversary of the date of the merger.
In addition, preferred stock (the "Junior Preferred Stock") held by a shareholder of ACT will continue as non-accruing preferred stock in the face amount of $2 million, senior in right of preference as to dividends and distributions in liquidation to the ACT Preferred Stock and common stock of ISI. The Junior Preferred Stock will be repayable by ISI on the fourth anniversary of the date of the merger, subject to accelerated payment from 25% of the net after tax profits of ISI available after payment of the ACT Debt. The Junior Preferred Stock will also be subject to reset upon the following conditions: the redemption value and liquidation preference of Junior Preferred Stock shall be increased if either the market capitalization of ISI or the amount to be paid by any third party for ISI values the common stock and any other equity securities or debt convertible into equity securities at (i) greater than $25 million, in which case the Junior Preferred Stock shall be increased to $2.75 million, or
(ii) greater than $35 million, in which case the Junior Preferred Stock shall be increased to $3.5 million (each a "Reset Event"). If not sooner redeemed and paid, the Junior Preferred Stock shall be fully redeemed and retired (subject only to the prior payment of the ACT Debt) at any time upon a change of control of the surviving company (excluding the transaction whereby the ACT stockholders convert their ACT Preferred Stock), or to the extent of the net proceeds from the sale of any equity securities of ISI exceeds $10.9 million.
In addition, on the merger date, three officers of ISI have agreed to grant ISI the option to terminate their employment agreements in exchange for (i) a one-year consulting agreement at the rate of $4,000 per month, (ii) common stock or options exercisable into approximately 1.25% of ISI and (iii) an amount by which 10% of the proceeds from the sale of certain assets of ISI exceed $200,000.
The Letter of Intent is non-binding and subject to the execution of definitive documents and due diligence. However, the parties have agreed to use good faith efforts to negotiate such agreements, and consummate the transaction as soon as reasonably practicable.
Based upon the outstanding and potential litigation between ISI and HEB described under the captions "Business of ISI - Legal Proceedings" and "Business of HEB - Legal Proceedings of HEB" and the general uncertainty of the current situation with HEB, ISI and Amphioxus have decided not to proceed with a potential transaction unless and until such situation is resolved in a manner that is acceptable to Amphioxus and ISI. In addition, as of the date hereof, neither Amphioxus nor ISI has completed its due diligence and ISI has not received the financial statements of Amphioxus. At such time, if any, that ISI and Amphioxus continue proceeding with a potential transaction, the due diligence process and the evaluation of the financial information will generate issues to be negotiated by the parties, including without limitation the form of any potential transaction and the representation and warranties, conditions to closing, and indemnifications contained in the form of documentation to be utilized in any potential transaction between the parties. There will be no transaction unless all such issues are successfully resolved by the parties, and there can be no assurance that the parties will be able to resolve all such issues.
For the reasons set forth above, ISI does not believe the potential transaction between ISI and Amphioxus is probable of completion at the present time. In addition, ISI believes that the failure to complete the asset sale would have a material adverse effect on the ISI stockholders because if the asset sale is not completed, ISI believes that it is likely that it will file for or be forced to resort to bankruptcy protection. In that event, ISI believes that it is extremely unlikely that ISI would be able to pay, or provide for the payment of, all of its liabilities and obligations, and therefore, the ISI Common Stock would have little or no value. See "Risk Factors - Risks Relating to ISI - Failure to Complete the Asset Sale Could Result in Bankruptcy." Unfortunately, because of ISI`s precarious financial situation, ISI believes that the ISI stockholders have but one reasonable choice - to vote in favor of the proposed asset sale to HEB. ISI believes that a vote against the asset sale would lead to the consequences set forth above and preclude the potential transaction with Amphioxus from proceeding . For that reason, ISI believes that the inclusion of financial information regarding Amphioxus would not be material to a stockholder`s voting decision with respect to the asset sale by ISI to HEB.
Relationships between ACT and ISI.
Ms. Margie Chassman owns 16,000,032 shares of ISI common stock representing approximately 42.9 % of the outstanding common stock of ISI. In addition, she has warrants to purchase an additional 16,666,667 shares of ISI common stock. Ms. Chassman also owns 16.65 % of the common stock of ACT. Neither Ms. Chassman nor any designee of Ms. Chassman is a member of the Board of Directors of ISI. Ms. Chassman has no contracts, arrangements, understandings or relationships with ISI with respect to the ISI common stock owned by her. Ms. Chassman has agreed to vote her shares of ISI common stock in the same proportion as the other ISI stockholders vote with respect to any transaction requiring stockholder approval between ACT and ISI.
Property
ISI owns two freestanding buildings comprising approximately 43,000 square feet that are located in New Brunswick, New Jersey. ISI uses the facilities for staff offices, manufacturing, quality control and research activities, and storage. ISI`s properties are subject to the Asset Purchase Agreement.
Legal Proceedings
In September 2003, the Company was sued in an action seeking foreclosure of the Company`s property due to non-payment of city property taxes, water and sewer charges aggregating approximately $225,000. The Company had until October 17, 2003 to answer the complaint. After such time, the plaintiff has the right to seek an order giving the Company 30 days to pay the unpaid taxes. As of the date hereof, no such order has been received by the Company. If the taxes remain unpaid after the date set by the court, the court may make the plaintiff the owner of the property. The property is subject to the sale of the Company`s assets to HEB. Under the terms of the Asset Purchase Agreement, if the Company`s tax obligations become due and payable, HEB has the option to (i) terminate the Asset Purchase Agreement or (ii) satisfy the tax obligations and proceed to closing after the other conditions of the Asset Purchase Agreement have been satisfied. On December 24, 2003, HEB advised the Company that it had purchased all of the Company`s outstanding tax obligations (resulting from unpaid city property taxes, sewer and water charges) and threatened to continue a foreclosure proceeding against the Company`s property if the Company does not move expeditiously to close the Asset Purchase Agreement. The Company has not decided what action it will take if HEB seeks to continue the foreclosure proceeding. However, any further litigation between the Company and HEB may have a material adverse effect on the Company and its stockholders because (i) the expenses of such litigation will drain the Company`s already limited assets,
(ii) in the event the market price of HEB common stock is adversely affected by such litigation, the value of the consideration to be received by the Company upon the closing (if any) of the Asset Purchase Agreement (the Company is to receive 487,028 shares of HEB common stock) would be reduced, and (iii) such litigation would reduce the likelihood of closing the Asset Purchase Agreement in the near future.. See Note 15 of Notes to Consolidated Condensed Financial Statements of ISI for the Quarter ended September 30, 2003 contained elsewhere herein.
On September 16, 2003, HEB filed and subsequently served and moved for expedited proceedings on a complaint filed in the Court Of Chancery of the State of Delaware, New Castle County, against ISI. The Complaint seeks specific performance, and declaratory and injunctive relief related to the Inventory and Asset Purchase Agreements with ISI. Specifically, HEB alleges that ISI has delayed its performance pursuant to the Inventory and Asset Purchase Agreement and, as a result, the Asset Purchase Agreement did not close within 180 days of the date of the execution of the agreements. Paragraph 7.7 of the Asset Purchase Agreement states that either party to the agreement may terminate the agreement if there is no closing within 180 days of the date of the agreement. HEB requested that the Court require ISI to specifically perform its obligations under the agreement or, in the alternative, that paragraph 7.7 of the agreement be eliminated or reformed to eliminate ISI`s ability to terminate pursuant to that paragraph. HEB also requested that ISI, as a result of its conduct, not be permitted to terminate the Asset Purchase Agreement pursuant to paragraph 7.7 or due to the passage of time. At a hearing held on September 29, 2003, the Court set a trial of the case for January 6-7, 2004 which was postponed until March 4-5, 2004. The parties have agreed that neither party shall have the right to terminate the Asset Purchase Agreement pursuant to paragraph 7.7 until the date which is at least two weeks following trial and only then, unless the Court has ruled, upon five days written notice to the other party. In response to HEB`s complaint, ISI has filed a motion to dismiss.
On March 11, 2003, ISI entered into the Inventory Agreement with HEB pursuant to which ISI sold HEB all of its inventory related to ALFERON N Injection and granted HEB a three year license to sell ALFERON N Injection in the United States. In addition, on March 11, 2003 substantially all of ISI`s employees became employees of HEB. ISI also entered into the Asset Purchase Agreement pursuant to which ISI has agreed to sell its property, plant, furniture, equipment, all customer lists, computer files, data and software, books and records, manufacturing records and procedures, approval processes and approvals with and by the U.S. Food and Drug Administration and all other property, patents, trademarks, and rights of every kind and nature owned or held by ISI relating to natural alpha interferon, its production, manufacture and sale. Upon completion of the Asset Purchase Agreement, ISI will not be involved in the natural alpha interferon business and will not have a manufacturing and research facility. Therefore, ISI`s remaining assets will consist of cash, 586,056 shares of HEB Common Stock (consisting of 99,028 shares currently held by ISI and an additional 487,028 shares of HEB Common Stock to be received upon completion of the Asset Purchase Agreement), a royalty from HEB equal to 6% of sales of products containing natural alpha interferon, a note receivable and a warrant to purchase shares of Amphioxus Cell Technologies, Inc. ("ACT"). ISI does not intend to distribute the HEB Common Stock to the ISI shareholders and has entered into a non-binding Letter of Intent to acquire ACT.
ACT Letter of Intent
On October 17, 2003, ISI and ACT entered into a non-binding letter of intent pursuant to which ISI (or a wholly owned subsidiary of ISI) will acquire ACT. The shareholders of ACT will receive preferred stock (the "ACT Preferred Stock") of ISI, convertible into a number of common shares of ISI equal to 75% of the fully diluted capitalization of ISI. The ACT Preferred Stock will be convertible at the option of the holder at any time, and subject to mandatory conversion if, prior to the date which is two years after the merger, the sum of the proceeds received from (i) the sale of the assets of ISI at the date of merger, and (ii) common equity capital raised at a pre-money valuation in excess of $10 million, exceed $2.5 million.
Certain debt (the "ACT Debt") aggregating approximately $2.9 million that is currently owed to shareholders of ACT will continue as secured non-interest bearing debt of ISI. The ACT Debt will be non-interest bearing and repayable by ISI on the fourth anniversary of the date of the merger, subject to accelerated payment of 25% of the net after tax profits of ACT over $1 million on a cumulative basis. The ACT Debt shall be fully payable upon a change of control of ISI (excluding the transactions whereby the ACT stockholders convert the ACT Preferred Stock). In addition, the ACT Debt shall also be repaid to the extent of the net proceeds from the sale of any equity securities of ISI exceeding $8 million. In addition, certain additional debt aggregating approximately $200,000 owed to a shareholder of ACT will be repayable on the fifth anniversary of the date of the merger.
In addition, preferred stock (the "Junior Preferred Stock") held by a shareholder of ACT will continue as non-accruing preferred stock in the face amount of $2 million, senior in right of preference as to dividends and distributions in liquidation to the ACT Preferred Stock and common stock of ISI. The Junior Preferred Stock will be repayable by ISI on the fourth anniversary of the date of the merger, subject to accelerated payment from 25% of the net after tax profits of ISI available after payment of the ACT Debt. The Junior Preferred Stock will also be subject to reset upon the following conditions: the redemption value and liquidation preference of Junior Preferred Stock shall be increased if either the market capitalization of ISI or the amount to be paid by any third party for ISI values the common stock and any other equity securities or debt convertible into equity securities at (i) greater than $25 million, in which case the Junior Preferred Stock shall be increased to $2.75 million, or
(ii) greater than $35 million, in which case the Junior Preferred Stock shall be increased to $3.5 million (each a "Reset Event"). If not sooner redeemed and paid, the Junior Preferred Stock shall be fully redeemed and retired (subject only to the prior payment of the ACT Debt) at any time upon a change of control of the surviving company (excluding the transaction whereby the ACT stockholders convert their ACT Preferred Stock), or to the extent of the net proceeds from the sale of any equity securities of ISI exceeds $10.9 million.
In addition, on the merger date, three officers of ISI have agreed to grant ISI the option to terminate their employment agreements in exchange for (i) a one-year consulting agreement at the rate of $4,000 per month, (ii) common stock or options exercisable into approximately 1.25% of ISI and (iii) an amount by which 10% of the proceeds from the sale of certain assets of ISI exceed $200,000.
The Letter of Intent is non-binding and subject to the execution of definitive documents and due diligence. However, the parties have agreed to use good faith efforts to negotiate such agreements, and consummate the transaction as soon as reasonably practicable.
Based upon the outstanding and potential litigation between ISI and HEB described under the captions "Business of ISI - Legal Proceedings" and "Business of HEB - Legal Proceedings of HEB" and the general uncertainty of the current situation with HEB, ISI and Amphioxus have decided not to proceed with a potential transaction unless and until such situation is resolved in a manner that is acceptable to Amphioxus and ISI. In addition, as of the date hereof, neither Amphioxus nor ISI has completed its due diligence and ISI has not received the financial statements of Amphioxus. At such time, if any, that ISI and Amphioxus continue proceeding with a potential transaction, the due diligence process and the evaluation of the financial information will generate issues to be negotiated by the parties, including without limitation the form of any potential transaction and the representation and warranties, conditions to closing, and indemnifications contained in the form of documentation to be utilized in any potential transaction between the parties. There will be no transaction unless all such issues are successfully resolved by the parties, and there can be no assurance that the parties will be able to resolve all such issues.
For the reasons set forth above, ISI does not believe the potential transaction between ISI and Amphioxus is probable of completion at the present time. In addition, ISI believes that the failure to complete the asset sale would have a material adverse effect on the ISI stockholders because if the asset sale is not completed, ISI believes that it is likely that it will file for or be forced to resort to bankruptcy protection. In that event, ISI believes that it is extremely unlikely that ISI would be able to pay, or provide for the payment of, all of its liabilities and obligations, and therefore, the ISI Common Stock would have little or no value. See "Risk Factors - Risks Relating to ISI - Failure to Complete the Asset Sale Could Result in Bankruptcy." Unfortunately, because of ISI`s precarious financial situation, ISI believes that the ISI stockholders have but one reasonable choice - to vote in favor of the proposed asset sale to HEB. ISI believes that a vote against the asset sale would lead to the consequences set forth above and preclude the potential transaction with Amphioxus from proceeding . For that reason, ISI believes that the inclusion of financial information regarding Amphioxus would not be material to a stockholder`s voting decision with respect to the asset sale by ISI to HEB.
Relationships between ACT and ISI.
Ms. Margie Chassman owns 16,000,032 shares of ISI common stock representing approximately 42.9 % of the outstanding common stock of ISI. In addition, she has warrants to purchase an additional 16,666,667 shares of ISI common stock. Ms. Chassman also owns 16.65 % of the common stock of ACT. Neither Ms. Chassman nor any designee of Ms. Chassman is a member of the Board of Directors of ISI. Ms. Chassman has no contracts, arrangements, understandings or relationships with ISI with respect to the ISI common stock owned by her. Ms. Chassman has agreed to vote her shares of ISI common stock in the same proportion as the other ISI stockholders vote with respect to any transaction requiring stockholder approval between ACT and ISI.
Property
ISI owns two freestanding buildings comprising approximately 43,000 square feet that are located in New Brunswick, New Jersey. ISI uses the facilities for staff offices, manufacturing, quality control and research activities, and storage. ISI`s properties are subject to the Asset Purchase Agreement.
Legal Proceedings
In September 2003, the Company was sued in an action seeking foreclosure of the Company`s property due to non-payment of city property taxes, water and sewer charges aggregating approximately $225,000. The Company had until October 17, 2003 to answer the complaint. After such time, the plaintiff has the right to seek an order giving the Company 30 days to pay the unpaid taxes. As of the date hereof, no such order has been received by the Company. If the taxes remain unpaid after the date set by the court, the court may make the plaintiff the owner of the property. The property is subject to the sale of the Company`s assets to HEB. Under the terms of the Asset Purchase Agreement, if the Company`s tax obligations become due and payable, HEB has the option to (i) terminate the Asset Purchase Agreement or (ii) satisfy the tax obligations and proceed to closing after the other conditions of the Asset Purchase Agreement have been satisfied. On December 24, 2003, HEB advised the Company that it had purchased all of the Company`s outstanding tax obligations (resulting from unpaid city property taxes, sewer and water charges) and threatened to continue a foreclosure proceeding against the Company`s property if the Company does not move expeditiously to close the Asset Purchase Agreement. The Company has not decided what action it will take if HEB seeks to continue the foreclosure proceeding. However, any further litigation between the Company and HEB may have a material adverse effect on the Company and its stockholders because (i) the expenses of such litigation will drain the Company`s already limited assets,
(ii) in the event the market price of HEB common stock is adversely affected by such litigation, the value of the consideration to be received by the Company upon the closing (if any) of the Asset Purchase Agreement (the Company is to receive 487,028 shares of HEB common stock) would be reduced, and (iii) such litigation would reduce the likelihood of closing the Asset Purchase Agreement in the near future.. See Note 15 of Notes to Consolidated Condensed Financial Statements of ISI for the Quarter ended September 30, 2003 contained elsewhere herein.
On September 16, 2003, HEB filed and subsequently served and moved for expedited proceedings on a complaint filed in the Court Of Chancery of the State of Delaware, New Castle County, against ISI. The Complaint seeks specific performance, and declaratory and injunctive relief related to the Inventory and Asset Purchase Agreements with ISI. Specifically, HEB alleges that ISI has delayed its performance pursuant to the Inventory and Asset Purchase Agreement and, as a result, the Asset Purchase Agreement did not close within 180 days of the date of the execution of the agreements. Paragraph 7.7 of the Asset Purchase Agreement states that either party to the agreement may terminate the agreement if there is no closing within 180 days of the date of the agreement. HEB requested that the Court require ISI to specifically perform its obligations under the agreement or, in the alternative, that paragraph 7.7 of the agreement be eliminated or reformed to eliminate ISI`s ability to terminate pursuant to that paragraph. HEB also requested that ISI, as a result of its conduct, not be permitted to terminate the Asset Purchase Agreement pursuant to paragraph 7.7 or due to the passage of time. At a hearing held on September 29, 2003, the Court set a trial of the case for January 6-7, 2004 which was postponed until March 4-5, 2004. The parties have agreed that neither party shall have the right to terminate the Asset Purchase Agreement pursuant to paragraph 7.7 until the date which is at least two weeks following trial and only then, unless the Court has ruled, upon five days written notice to the other party. In response to HEB`s complaint, ISI has filed a motion to dismiss.
Ich werde mich nun aus dem Board zurückziehen da mir eh keiner Meinungen schreibt.
Nicht das ich nacher noch schuld bin wenn es nichts wird.........WENN ABER DOCH DANN GEHT DIE PARTY AB
Aktuell 0,04...High 0,05.....
es geht doch....
Grüsse ....melde mich wieder nach dem SHAREHOLDERMEETING
-mal sehen was der Kurs bis dahin macht.
Good Luck
Torni
Nicht das ich nacher noch schuld bin wenn es nichts wird.........WENN ABER DOCH DANN GEHT DIE PARTY AB
Aktuell 0,04...High 0,05.....
es geht doch....
Grüsse ....melde mich wieder nach dem SHAREHOLDERMEETING
-mal sehen was der Kurs bis dahin macht.
Good Luck
Torni
Achtung.........
Sorry ich kann es nicht lassen........117K
0,06 BBBBUUUMMMMMMMMMMMM
50%%%%%%%%%%%%
Sorry ich kann es nicht lassen........117K
0,06 BBBBUUUMMMMMMMMMMMM
50%%%%%%%%%%%%
Jetzt ist das Teil auf 0,055......+35%
Sagt mal sind da nur Käufer aus USA????
Egal...es fängt erst an
Sagt mal sind da nur Käufer aus USA????
Egal...es fängt erst an
Date - Open- High -Low -Last -Change - Volume % Change
02/11/04´-- 0.0350- 0.0600 -0.0350- 0.0550-- +0.0150 174450- +37.50%
Composite Indicator
Trend Spotter (TM) Buy
Short Term Indicators
7 Day Average Directional Indicator Buy
10 - 8 Day Moving Average Hilo Channel Buy
20 Day Moving Average vs Price Hold
20 - 50 Day MACD Oscillator Hold
20 Day Bollinger Bands Hold
Short Term Indicators Average: 40% - Buy
20-Day Average Volume - 28150
Medium Term Indicators
40 Day Commodity Channel Index Buy
50 Day Moving Average vs Price Buy
20 - 100 Day MACD Oscillator Hold
50 Day Parabolic Time/Price Buy
Medium Term Indicators Average: 75% - Buy
50-Day Average Volume - 19348
Long Term Indicators
60 Day Commodity Channel Index Buy
100 Day Moving Average vs Price Hold
50 - 100 Day MACD Oscillator Hold
Long Term Indicators Average: 33% - Buy
100-Day Average Volume - 27317
Overall Average: 56% - Buy
Price- Support- Pivot- Point- Resistance
0.04- 0.03- 0.04- 0.05
Aktuell 0,055
02/11/04´-- 0.0350- 0.0600 -0.0350- 0.0550-- +0.0150 174450- +37.50%
Composite Indicator
Trend Spotter (TM) Buy
Short Term Indicators
7 Day Average Directional Indicator Buy
10 - 8 Day Moving Average Hilo Channel Buy
20 Day Moving Average vs Price Hold
20 - 50 Day MACD Oscillator Hold
20 Day Bollinger Bands Hold
Short Term Indicators Average: 40% - Buy
20-Day Average Volume - 28150
Medium Term Indicators
40 Day Commodity Channel Index Buy
50 Day Moving Average vs Price Buy
20 - 100 Day MACD Oscillator Hold
50 Day Parabolic Time/Price Buy
Medium Term Indicators Average: 75% - Buy
50-Day Average Volume - 19348
Long Term Indicators
60 Day Commodity Channel Index Buy
100 Day Moving Average vs Price Hold
50 - 100 Day MACD Oscillator Hold
Long Term Indicators Average: 33% - Buy
100-Day Average Volume - 27317
Overall Average: 56% - Buy
Price- Support- Pivot- Point- Resistance
0.04- 0.03- 0.04- 0.05
Aktuell 0,055
Bin auch noch drin - aber richtig freue ich mich erst >0,14 ... denn da bin ich eingestiegen...
Das glaube ich gar nicht. Gestriger Anstieg um 37% mit einem absoluten Volumen von 180K auf 0,055
aber was mich wundert ist das sich keiner zu Wort meldet.
Hier ist echt Totenstille und ISI steigt.
Hat wohl keiner Interesse. Nun dann sei es so
Muss ich ja dann auch nichts mehr schreiben.
Also der nächste Anstieg folgt bestimmt. Ich bin der Meinung das es erst so richtig losgeht. Schaut Euch mal das vergangene Jahr an und betrachtet die grünen Striche was die Volumenkäufe betrifft
Also wenn ich das addiere erhalte ich zu 75% versteckte Käufe oder es ist alles nur Mmanipuliert. Was ich aber bei diesen Aussichten nicht glaube.
Gestern hatten wir in kürzester Zeit über 30 Trades bei 0,05 und 0,06 Da hat sich einer eingedeckt.
Also bis dann.....mal ne richtige Meinung wäre nicht schlecht.
Danke und Grüsse
Torni
aber was mich wundert ist das sich keiner zu Wort meldet.
Hier ist echt Totenstille und ISI steigt.
Hat wohl keiner Interesse. Nun dann sei es so
Muss ich ja dann auch nichts mehr schreiben.
Also der nächste Anstieg folgt bestimmt. Ich bin der Meinung das es erst so richtig losgeht. Schaut Euch mal das vergangene Jahr an und betrachtet die grünen Striche was die Volumenkäufe betrifft
Also wenn ich das addiere erhalte ich zu 75% versteckte Käufe oder es ist alles nur Mmanipuliert. Was ich aber bei diesen Aussichten nicht glaube.
Gestern hatten wir in kürzester Zeit über 30 Trades bei 0,05 und 0,06 Da hat sich einer eingedeckt.
Also bis dann.....mal ne richtige Meinung wäre nicht schlecht.
Danke und Grüsse
Torni
Einen habe ich aber noch
IFSC - INTERFERON SCI (OTC)
Date Open High Low Last Change Volume % Change
02/11/04 0.04 0.06 0.04 0.05 +0.02 181600 +37.50%
Composite Indicator -- Signal -- -- Strength -- -- Direction --
Trend Spotter (TM) Buy Maximum Strongest
Short Term Indicators
7 Day Average Directional Indicator Buy Average Strongest
10 - 8 Day Moving Average Hilo Channel Buy Average Strongest
20 Day Moving Average vs Price Buy Maximum Strongest
20 - 50 Day MACD Oscillator Hold Steady
20 Day Bollinger Bands Buy Maximum Strongest
Short Term Indicators Average: 80% - Buy
Medium Term Indicators
40 Day Commodity Channel Index Buy Strong Strongest
50 Day Moving Average vs Price Buy Maximum Strongest
20 - 100 Day MACD Oscillator Hold Steady
50 Day Parabolic Time/Price Buy Average Strongest
Medium Term Indicators Average: 75% - Buy
Long Term Indicators
60 Day Commodity Channel Index Buy Maximum Strongest
100 Day Moving Average vs Price Buy Maximum Strongest
50 - 100 Day MACD Oscillator Hold Steady
Long Term Indicators Average: 67% - Buy
Overall Average: 80% - Buy
IFSC - INTERFERON SCI (OTC)
Date Open High Low Last Change Volume % Change
02/11/04 0.04 0.06 0.04 0.05 +0.02 181600 +37.50%
Composite Indicator -- Signal -- -- Strength -- -- Direction --
Trend Spotter (TM) Buy Maximum Strongest
Short Term Indicators
7 Day Average Directional Indicator Buy Average Strongest
10 - 8 Day Moving Average Hilo Channel Buy Average Strongest
20 Day Moving Average vs Price Buy Maximum Strongest
20 - 50 Day MACD Oscillator Hold Steady
20 Day Bollinger Bands Buy Maximum Strongest
Short Term Indicators Average: 80% - Buy
Medium Term Indicators
40 Day Commodity Channel Index Buy Strong Strongest
50 Day Moving Average vs Price Buy Maximum Strongest
20 - 100 Day MACD Oscillator Hold Steady
50 Day Parabolic Time/Price Buy Average Strongest
Medium Term Indicators Average: 75% - Buy
Long Term Indicators
60 Day Commodity Channel Index Buy Maximum Strongest
100 Day Moving Average vs Price Buy Maximum Strongest
50 - 100 Day MACD Oscillator Hold Steady
Long Term Indicators Average: 67% - Buy
Overall Average: 80% - Buy
Schaut Euch nur mal das Verhältnis rot -grün an
Das sind nun 7 Monate ....Wer hat da gekauft?????
Also einen kenne ich schon...Ich...
Das sind nun 7 Monate ....Wer hat da gekauft?????
Also einen kenne ich schon...Ich...
Company News and Press Releases From Other Sources:
INTERFERON SCIENCES INC, (SC 13G/A) Statement of Ownership Filed By ALPHA CAPITAL AKTIENGESELLSCHAFT
--------------------------------------------------------------------------------
--------------------------------------------------------------------------------
UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
WASHINGTON, D.C. 20549
SCHEDULE 13G/A
UNDER THE SECURITIES EXCHANGE ACT OF 1934
(AMENDMENT NO. 2)*
Interferon Sciences, Inc.
--------------------------------------------------------------------------------
(Name of Issuer)
COMMON STOCK, $.01 PAR VALUE
--------------------------------------------------------------------------------
(Title of Class of Securities)
458903408
--------------------------------------------------------------------------------
(CUSIP Number)
*The remainder of this cover page shall be filled out for a reporting person`s initial filing on this form with respect to the subject class of securities, and for any subsequent amendment containing information which would alter the disclosures provided in a prior cover page.
The information required in the remainder of this cover page shall not be deemed to be "filed" for the purpose of Section 18 of the Securities Exchange Act of 1934 ("Act") or otherwise subject to the liabilities of that section of the Act but shall be subject to all other provisions of the Act (however, see the Notes).
(Continued on following page(s))
--------------------------------------------------------------------------------
Page 1 of 4 Pages
--------------------------------------------------------------------------------
----------------------------- ------------------------------
CUSIP No. 458903408 13G/A Page 2 of 4 Pages
----------------------------- ------------------------------
--------------------------------------------------------------------------------
1. NAMES OF REPORTING PERSON
S.S. OR I.R.S. IDENTIFICATION NO. OF ABOVE PERSON
Alpha Capital Aktiengesellschaft
--------------------------------------------------------------------------------
2. CHECK THE APPROPRIATE BOX IF A MEMBER OF A GROUP:
(a) |_|
(b) |_|
--------------------------------------------------------------------------------
3. SEC USE ONLY
--------------------------------------------------------------------------------
4. CITIZENSHIP OR PLACE OF ORGANIZATION
Liechtenstein
--------------------------------------------------------------------------------
5. SOLE VOTING POWER
NUMBER OF 6,221,089 shares of Common Stock
SHARES --------------------------------------------------------
BENEFICIALLY 6. SHARED VOTING POWER
OWNED BY None
EACH --------------------------------------------------------
REPORTING 7. SOLE DISPOSITIVE POWER
PERSON WITH 6,221,089 shares of Common Stock
--------------------------------------------------------
8. SHARED DISPOSITIVE POWER
None
--------------------------------------------------------------------------------
9. AGGREGATE AMOUNT BENEFICIALLY OWNED BY EACH REPORTING
PERSON
6,221,089 shares of Common Stock
--------------------------------------------------------------------------------
10. CHECK BOX IF THE AGGREGATE AMOUNT IN ROW (9) EXCLUDES
CERTAIN SHARES |X|
The aggregate amount in Row 9 represents the maximum amount of shares
that Alpha Capital can beneficially control under a contractually
stipulated 9.9% ownership restriction. The full exercise of Alpha
Capital`s Warrants would exceed this restriction.
--------------------------------------------------------------------------------
11. PERCENT OF CLASS REPRESENTED BY AMOUNT IN ROW 9
9.9%
--------------------------------------------------------------------------------
12. TYPE OF REPORTING PERSON
CO
-------------------------------------------------------------------------------
--------------------------------------------------------------------------------
CUSIP NO. 458903408 PAGE 3 OF 4 PAGES
--- ---
ITEM 1 (a) NAME OF ISSUER: Interferon Sciences, Inc.
ITEM 1 (b) ADDRESS OF ISSUER`S PRINCIPAL EXECUTIVE OFFICES:
783 Jersey Avenue, New Brunswick, NJ 08901
ITEM 2 (a) NAME OF PERSON FILING: Alpha Capital Aktiengesellschaft
ITEM 2 (b) ADDRESS OF PRINCIPAL BUSINESS OFFICE OR, IF NONE, RESIDENCE:
Pradafant 7, Furstentums 9490, Vaduz, Liechtenstein
ITEM 2 (c) CITIZENSHIP: Liechtenstein
ITEM 2 (d) TITLE OF CLASS OF SECURITIES: Common Stock, $.01 par value
ITEM 2 (e) CUSIP NUMBER: 458903408
ITEM 3 IF THIS STATEMENT IS FILED PURSUANT TO RULE 13D-1(B) OR
13D-2(B): Not applicable
ITEM 4 OWNERSHIP
(a) AMOUNT BENEFICIALLY OWNED: 6,221,089 Shares of Common Stock
(b) PERCENT OF CLASS: 9.9%
(c) NUMBER OF SHARES AS TO WHICH SUCH PERSON HAS:
(i) SOLE POWER TO VOTE OR DIRECT THE VOTE
6,221,089 Shares
(ii) SHARED POWER TO VOTE OR DIRECT THE VOTE
0 Shares
(iii) SOLE POWER TO DISPOSE OR TO DIRECT THE DISPOSITION OF
6,221,089 Shares
(iv) SHARED POWER TO DISPOSE OR TO DIRECT THE DISPOSITION OF
0 Shares
--------------------------------------------------------------------------------
CUSIP NO. 458903408 PAGE 4 OF 4 PAGES
--- ---
Strong buy
INTERFERON SCIENCES INC, (SC 13G/A) Statement of Ownership Filed By ALPHA CAPITAL AKTIENGESELLSCHAFT
--------------------------------------------------------------------------------
--------------------------------------------------------------------------------
UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
WASHINGTON, D.C. 20549
SCHEDULE 13G/A
UNDER THE SECURITIES EXCHANGE ACT OF 1934
(AMENDMENT NO. 2)*
Interferon Sciences, Inc.
--------------------------------------------------------------------------------
(Name of Issuer)
COMMON STOCK, $.01 PAR VALUE
--------------------------------------------------------------------------------
(Title of Class of Securities)
458903408
--------------------------------------------------------------------------------
(CUSIP Number)
*The remainder of this cover page shall be filled out for a reporting person`s initial filing on this form with respect to the subject class of securities, and for any subsequent amendment containing information which would alter the disclosures provided in a prior cover page.
The information required in the remainder of this cover page shall not be deemed to be "filed" for the purpose of Section 18 of the Securities Exchange Act of 1934 ("Act") or otherwise subject to the liabilities of that section of the Act but shall be subject to all other provisions of the Act (however, see the Notes).
(Continued on following page(s))
--------------------------------------------------------------------------------
Page 1 of 4 Pages
--------------------------------------------------------------------------------
----------------------------- ------------------------------
CUSIP No. 458903408 13G/A Page 2 of 4 Pages
----------------------------- ------------------------------
--------------------------------------------------------------------------------
1. NAMES OF REPORTING PERSON
S.S. OR I.R.S. IDENTIFICATION NO. OF ABOVE PERSON
Alpha Capital Aktiengesellschaft
--------------------------------------------------------------------------------
2. CHECK THE APPROPRIATE BOX IF A MEMBER OF A GROUP:
(a) |_|
(b) |_|
--------------------------------------------------------------------------------
3. SEC USE ONLY
--------------------------------------------------------------------------------
4. CITIZENSHIP OR PLACE OF ORGANIZATION
Liechtenstein
--------------------------------------------------------------------------------
5. SOLE VOTING POWER
NUMBER OF 6,221,089 shares of Common Stock
SHARES --------------------------------------------------------
BENEFICIALLY 6. SHARED VOTING POWER
OWNED BY None
EACH --------------------------------------------------------
REPORTING 7. SOLE DISPOSITIVE POWER
PERSON WITH 6,221,089 shares of Common Stock
--------------------------------------------------------
8. SHARED DISPOSITIVE POWER
None
--------------------------------------------------------------------------------
9. AGGREGATE AMOUNT BENEFICIALLY OWNED BY EACH REPORTING
PERSON
6,221,089 shares of Common Stock
--------------------------------------------------------------------------------
10. CHECK BOX IF THE AGGREGATE AMOUNT IN ROW (9) EXCLUDES
CERTAIN SHARES |X|
The aggregate amount in Row 9 represents the maximum amount of shares
that Alpha Capital can beneficially control under a contractually
stipulated 9.9% ownership restriction. The full exercise of Alpha
Capital`s Warrants would exceed this restriction.
--------------------------------------------------------------------------------
11. PERCENT OF CLASS REPRESENTED BY AMOUNT IN ROW 9
9.9%
--------------------------------------------------------------------------------
12. TYPE OF REPORTING PERSON
CO
-------------------------------------------------------------------------------
--------------------------------------------------------------------------------
CUSIP NO. 458903408 PAGE 3 OF 4 PAGES
--- ---
ITEM 1 (a) NAME OF ISSUER: Interferon Sciences, Inc.
ITEM 1 (b) ADDRESS OF ISSUER`S PRINCIPAL EXECUTIVE OFFICES:
783 Jersey Avenue, New Brunswick, NJ 08901
ITEM 2 (a) NAME OF PERSON FILING: Alpha Capital Aktiengesellschaft
ITEM 2 (b) ADDRESS OF PRINCIPAL BUSINESS OFFICE OR, IF NONE, RESIDENCE:
Pradafant 7, Furstentums 9490, Vaduz, Liechtenstein
ITEM 2 (c) CITIZENSHIP: Liechtenstein
ITEM 2 (d) TITLE OF CLASS OF SECURITIES: Common Stock, $.01 par value
ITEM 2 (e) CUSIP NUMBER: 458903408
ITEM 3 IF THIS STATEMENT IS FILED PURSUANT TO RULE 13D-1(B) OR
13D-2(B): Not applicable
ITEM 4 OWNERSHIP
(a) AMOUNT BENEFICIALLY OWNED: 6,221,089 Shares of Common Stock
(b) PERCENT OF CLASS: 9.9%
(c) NUMBER OF SHARES AS TO WHICH SUCH PERSON HAS:
(i) SOLE POWER TO VOTE OR DIRECT THE VOTE
6,221,089 Shares
(ii) SHARED POWER TO VOTE OR DIRECT THE VOTE
0 Shares
(iii) SOLE POWER TO DISPOSE OR TO DIRECT THE DISPOSITION OF
6,221,089 Shares
(iv) SHARED POWER TO DISPOSE OR TO DIRECT THE DISPOSITION OF
0 Shares
--------------------------------------------------------------------------------
CUSIP NO. 458903408 PAGE 4 OF 4 PAGES
--- ---
Strong buy
@all es wird wieder Zeit sich zu Wort zu melden
Seit meinem ersten Posting das IFSC nach oben geht , hat sich bestättigt das etwas ganz grosses kommen wird
Ich hatte Euch bei 0,03 geraten einzusteigen....Nun sind wir bereits auf 0,06 und waren schon bei 0,07........
ISI steigt und steigt....Ich kann nur raten einzusteigen bevor der grosse run kommt.
Schaut Euch mal ganz genau den Chart an........und den der letzten Jahre...
Viel Erfolg und bis dann.
News gibt es auch schon wieder
Da sich hier wohl keiner meldet ist auch kaum einer investiert....
Na dann AUFGEHTS........
Na dann AUFGEHTS........
@all die Interesse haben.
Lasst Euch ja nicht von der gestrigen roten Linie beeindrucken.
Es wurde über 80K gekauft...
60K bei o,o7
Am Schluss wurde der Kurs mit lächerlichen 2 orders a 200 Stück nach unten auf 0,06 gedrückt
Viel Erfolg beinm Kauf....
Grüsse
Lasst Euch ja nicht von der gestrigen roten Linie beeindrucken.
Es wurde über 80K gekauft...
60K bei o,o7
Am Schluss wurde der Kurs mit lächerlichen 2 orders a 200 Stück nach unten auf 0,06 gedrückt
Viel Erfolg beinm Kauf....
Grüsse
Hallo Tornado!
So, ich hoffe, daß ich jetzt mal in die Gänge komme.
Ruf jetzt mal den Broker an und dann seh ich mal weiter.
Will eigentlich noch den heutigen Tag abwarten.
Danke für Deine Infos, auch zu Deiner Situation.
Wie Du schon richtig geschrieben hast, gings noch mal runter.
Ich dachte erst es wäre nur ein trade mit lächerlichen 200St. gewesen.
Zu DGENQ kann ich leider nur sagen, insolventer Schrottladen,läuft aber trotzdem, wie so viele Imbißbuden.
ich melde mich wahscheinlich später nochmal wieder.
Ich wünsch Dir erfolgreiche trades, biss dann
sm
So, ich hoffe, daß ich jetzt mal in die Gänge komme.
Ruf jetzt mal den Broker an und dann seh ich mal weiter.
Will eigentlich noch den heutigen Tag abwarten.
Danke für Deine Infos, auch zu Deiner Situation.
Wie Du schon richtig geschrieben hast, gings noch mal runter.
Ich dachte erst es wäre nur ein trade mit lächerlichen 200St. gewesen.
Zu DGENQ kann ich leider nur sagen, insolventer Schrottladen,läuft aber trotzdem, wie so viele Imbißbuden.
ich melde mich wahscheinlich später nochmal wieder.
Ich wünsch Dir erfolgreiche trades, biss dann
sm
QUOTE: Interferon Sciences Inc. (OBB : IFSC)
weiß vielleicht jemand einen alternativen link zu
smallcapcenter.com?
Ich finde keine genauen Bid/Ask`s.
IFSC finde ich auch auf pinksheets, aber auch kein Bid/Ask.
leider konnte ich auch gestern Abend keine After-hour
Kurse finden.
Bei nasdaq.com kommt no extended trading for IFSC,
hab ich auch bisher nirgends gesehen, daß man die außerbörslich handeln kann.
wäre dankbar für nen kleinen Tip!
weiß vielleicht jemand einen alternativen link zu
smallcapcenter.com?
Ich finde keine genauen Bid/Ask`s.
IFSC finde ich auch auf pinksheets, aber auch kein Bid/Ask.
leider konnte ich auch gestern Abend keine After-hour
Kurse finden.
Bei nasdaq.com kommt no extended trading for IFSC,
hab ich auch bisher nirgends gesehen, daß man die außerbörslich handeln kann.
wäre dankbar für nen kleinen Tip!
Hallo Schlumpfomat...oder so
Bin leider erst gerade online - WORKING
Zu Deinen Fragen:
IFSC wird derzeit nur über PINK sheets gehandelt.
Es gibt nur eine Möglichkeit zu kaufen und zwar über USA.
Consors funktioniert wunderbar. Was andere so machen weis ich leider nicht.
Bei Consors gibst Du einfach 918064....(WKN an) und 2 min später ist schon ausgeführt oder nicht
Nun es ist so dass Pink sheets sehr unterschiedliche Broker hat und Du nicht immer bedient wirst auch wenn der Kurs erreich war. Wer zuerst da steht wird zuerst bedient...AMILAND Wenn Du aber in den ASK kaufst oder Bid verkaufst ist die Möglichkeit sehr gross dass ausgeführt wird. Umgerechnet wird dann erst später....DOLLAR/EURO.
Hier der Link:
http://www.pinksheets.com/quote/quote.jsp?symbol=IFSC
Ich dachte Du warst das mit den 50K bei 0,065
Nun denn Viel Glück
Bin leider erst gerade online - WORKING
Zu Deinen Fragen:
IFSC wird derzeit nur über PINK sheets gehandelt.
Es gibt nur eine Möglichkeit zu kaufen und zwar über USA.
Consors funktioniert wunderbar. Was andere so machen weis ich leider nicht.
Bei Consors gibst Du einfach 918064....(WKN an) und 2 min später ist schon ausgeführt oder nicht
Nun es ist so dass Pink sheets sehr unterschiedliche Broker hat und Du nicht immer bedient wirst auch wenn der Kurs erreich war. Wer zuerst da steht wird zuerst bedient...AMILAND Wenn Du aber in den ASK kaufst oder Bid verkaufst ist die Möglichkeit sehr gross dass ausgeführt wird. Umgerechnet wird dann erst später....DOLLAR/EURO.
Hier der Link:
http://www.pinksheets.com/quote/quote.jsp?symbol=IFSC
Ich dachte Du warst das mit den 50K bei 0,065
Nun denn Viel Glück
Hi Tornado 34!
Danke für den link, funzt gut, hab ich gleich gebookmarkt.
0,065?
too much for me
entweder werde ich montag mein limit ändern oder wie
des öfteren zugucken
toll, daß ich jetzt endlich Bid/Ask sehen kann!
Danke und bis später
schlumpfiger gruß
Danke für den link, funzt gut, hab ich gleich gebookmarkt.
0,065?
too much for me
entweder werde ich montag mein limit ändern oder wie
des öfteren zugucken
toll, daß ich jetzt endlich Bid/Ask sehen kann!
Danke und bis später
schlumpfiger gruß
Du siehst aber nicht wieviel jeweils stehen und was dazwischen steht.
Na ja fürs erste läuft IFSC genau so wie ich es schon geschrieben habe.
BID zieht nach und es wurden heute ca. 60K bei o,o65 gekauft...so wie jeden Tag halt
Grüsse
Na ja fürs erste läuft IFSC genau so wie ich es schon geschrieben habe.
BID zieht nach und es wurden heute ca. 60K bei o,o65 gekauft...so wie jeden Tag halt
Grüsse
@schlumpf
habe die per postfach...noch einen heissen Link geschickt
habe die per postfach...noch einen heissen Link geschickt
total nett von Dir mir den link zu schicken!
echt Klasse!
ich könnte mich schon wieder ärgern, daß ich mein
Megageizhals Limit mit 0,004$ eingegeben habe.
Bitte nicht lachen, Änderung am Montag sehr wahscheinlich
und kostet nix. 0,005$ wäre schon ok gewesen, gruzifix
Sehr wahrscheinlich, wirst Du Recht mit den Bid/Ask
Prognosen behalten, bei einigen ausgesuchten Mini-Bios
decken sich,unter sehr geringem Volumen Hartgesottene ein.
Leider macht Heute mal wieder der Gesamtmarkt schlapp, was
die Erwähnten Minis aber wenig stört.
Bist Du auch bei den Tiefs in IFSC eingestiegen?
Oder nur bei den Allzeittiefs???
Ist Dein Durchschnitt unter 0,05$?
Toll, daß Du hier so viele Infos gepostet hast!!!
schlumpfomat
echt Klasse!
ich könnte mich schon wieder ärgern, daß ich mein
Megageizhals Limit mit 0,004$ eingegeben habe.
Bitte nicht lachen, Änderung am Montag sehr wahscheinlich
und kostet nix. 0,005$ wäre schon ok gewesen, gruzifix
Sehr wahrscheinlich, wirst Du Recht mit den Bid/Ask
Prognosen behalten, bei einigen ausgesuchten Mini-Bios
decken sich,unter sehr geringem Volumen Hartgesottene ein.
Leider macht Heute mal wieder der Gesamtmarkt schlapp, was
die Erwähnten Minis aber wenig stört.
Bist Du auch bei den Tiefs in IFSC eingestiegen?
Oder nur bei den Allzeittiefs???
Ist Dein Durchschnitt unter 0,05$?
Toll, daß Du hier so viele Infos gepostet hast!!!
schlumpfomat
Ach schlumpfomat...ich kann Dir leider nicht meine kompletten Finanziellen Angelegenheiten erzählen.
Aber mein Schnitt ist schon ok.
Hmmmmmm gerade wieder 50K 0,07.........
Es geht los....
Aber mein Schnitt ist schon ok.
Hmmmmmm gerade wieder 50K 0,07.........
Es geht los....
Da deckt sich einer oder Viele...gewaltig seit Tagen ein.
Wir steigen und steigen und steigen...........
Was geht??
Erlebe ich doch noch den Mega-Hype von 2000...?
Das fing genauso an...
Ich kann mir nicht helfen doch steigt ein solange es noch sooooo billig ist
16,66%
Wir steigen und steigen und steigen...........
Was geht??
Erlebe ich doch noch den Mega-Hype von 2000...?
Das fing genauso an...
Ich kann mir nicht helfen doch steigt ein solange es noch sooooo billig ist
16,66%
Entschuldige bitte meine indiskrete Frage.
Glückwunsch von mir zu dem erfolgreichen Tag, ab
Montag bin ich dann auch dabei bei 0,07$ *grummel
schönes Wochenende!
Glückwunsch von mir zu dem erfolgreichen Tag, ab
Montag bin ich dann auch dabei bei 0,07$ *grummel
schönes Wochenende!
Wünsche ich auch
Look @ the BID and ASK.......
ASK 0,08 ......Und es wird weitergehen
Grüsse
Look @ the BID and ASK.......
ASK 0,08 ......Und es wird weitergehen
Grüsse
#1 wär ein halbwegs zeitgerechter Tip gewesen
ist selten, meist kommen sie zu spät
ist selten, meist kommen sie zu spät
was heisst hier wäre?
Es war.Als ich am 9.2.04 postete es ist Zeit...da standen wir noch weit unter 0,07......
Zudem postete ich schon letztes Jahr das was kommen wird.
Wer zu spät kommt muss halt mehr bezahlen
Aber ich kann Euch trösten...
schaut Euch mal den chart von 2000 an und was da innerhalb von 2 Wochen pssierte.
0,30-5,50... Da wollte auch keiner einsteigen
Also noch ist es billig.
Ciao und schönen Sonntag
Es war.Als ich am 9.2.04 postete es ist Zeit...da standen wir noch weit unter 0,07......
Zudem postete ich schon letztes Jahr das was kommen wird.
Wer zu spät kommt muss halt mehr bezahlen
Aber ich kann Euch trösten...
schaut Euch mal den chart von 2000 an und was da innerhalb von 2 Wochen pssierte.
0,30-5,50... Da wollte auch keiner einsteigen
Also noch ist es billig.
Ciao und schönen Sonntag
Wer hier auf einen besseren Einstiegskurs wartet, wartet vergebens.
Schaut euch mal den RSI auf 6 Monate an.
Mich würde es ja nicht einmal wundern wenn IFSC jemand übernimmt.
Da wird seit Monaten nichts verkauft........oder wie erklärt Ihr Euch einen solchen RSI Verlauf
Schaut euch mal den RSI auf 6 Monate an.
Mich würde es ja nicht einmal wundern wenn IFSC jemand übernimmt.
Da wird seit Monaten nichts verkauft........oder wie erklärt Ihr Euch einen solchen RSI Verlauf
Achtung
Schon wieder News.........Anscheinend haben da einige grössere Investoren auch Interesse
Buy Buy.........Strong buy
SCHEDULE 13G/A
UNDER THE SECURITIES EXCHANGE ACT OF 1934
(AMENDMENT NO. 3)*
Interferon Sciences, Inc.
--------------------------------------------------------------------------------
(Name of Issuer)
COMMON STOCK, $.01 PAR VALUE
--------------------------------------------------------------------------------
(Title of Class of Securities)
458903408
--------------------------------------------------------------------------------
(CUSIP Number)
*The remainder of this cover page shall be filled out for a reporting person`s initial filing on this form with respect to the subject class of securities, and for any subsequent amendment containing information which would alter the disclosures provided in a prior cover page.
The information required in the remainder of this cover page shall not be deemed to be "filed" for the purpose of Section 18 of the Securities Exchange Act of 1934 ("Act") or otherwise subject to the liabilities of that section of the Act but shall be subject to all other provisions of the Act (however, see the Notes).
(Continued on following page(s))
--------------------------------------------------------------------------------
Page 1 of 4 Pages
--------------------------------------------------------------------------------
----------------------------- ------------------------------
CUSIP No. 458903408 13G/A Page 2 of 4 Pages
----------------------------- ------------------------------
--------------------------------------------------------------------------------
1. NAMES OF REPORTING PERSON
S.S. OR I.R.S. IDENTIFICATION NO. OF ABOVE PERSON
Celeste Trust Reg.
--------------------------------------------------------------------------------
2. CHECK THE APPROPRIATE BOX IF A MEMBER OF A GROUP:
(a) |_|
(b) |_|
--------------------------------------------------------------------------------
3. SEC USE ONLY
--------------------------------------------------------------------------------
4. CITIZENSHIP OR PLACE OF ORGANIZATION
Liechtenstein
--------------------------------------------------------------------------------
5. SOLE VOTING POWER
NUMBER OF 1,467,402 shares of Common Stock
SHARES --------------------------------------------------------
BENEFICIALLY 6. SHARED VOTING POWER
OWNED BY None
EACH --------------------------------------------------------
REPORTING 7. SOLE DISPOSITIVE POWER
PERSON WITH 1,467,402 shares of Common Stock
--------------------------------------------------------
8. SHARED DISPOSITIVE POWER
None
--------------------------------------------------------------------------------
9. AGGREGATE AMOUNT BENEFICIALLY OWNED BY EACH REPORTING
PERSON
1,467,402 shares of Common Stock
--------------------------------------------------------------------------------
10. CHECK BOX IF THE AGGREGATE AMOUNT IN ROW (9) EXCLUDES
CERTAIN SHARES |_|
--------------------------------------------------------------------------------
11. PERCENT OF CLASS REPRESENTED BY AMOUNT IN ROW 9
7.1%
--------------------------------------------------------------------------------
12. TYPE OF REPORTING PERSON
CO
-------------------------------------------------------------------------------
--------------------------------------------------------------------------------
CUSIP NO. 458903408 PAGE 3 OF 4 PAGES
--- ---
ITEM 1 (a) NAME OF ISSUER: Interferon Sciences, Inc.
ITEM 1 (b) ADDRESS OF ISSUER`S PRINCIPAL EXECUTIVE OFFICES:
783 Jersey Avenue, New Brunswick, NJ 08901
ITEM 2 (a) NAME OF PERSON FILING: Celeste Trust Reg.
ITEM 2 (b) ADDRESS OF PRINCIPAL BUSINESS OFFICE OR, IF NONE, RESIDENCE:
Trevisa-Treuhand-Anstalt, Landstrasse 8, 9496 Furstentums,
Balzers, Liechtenstein
ITEM 2 (c) CITIZENSHIP: Liechtenstein
ITEM 2 (d) TITLE OF CLASS OF SECURITIES: Common Stock, $.01 par value
ITEM 2 (e) CUSIP NUMBER: 458903408
ITEM 3 IF THIS STATEMENT IS FILED PURSUANT TO RULE 13D-1(B) OR
13D-2(B): Not applicable
ITEM 4 OWNERSHIP
(a) AMOUNT BENEFICIALLY OWNED: 1,467,402 Shares of Common Stock
(b) PERCENT OF CLASS: 7.1%
(c) NUMBER OF SHARES AS TO WHICH SUCH PERSON HAS:
(i) SOLE POWER TO VOTE OR DIRECT THE VOTE
1,467,402 Shares
(ii) SHARED POWER TO VOTE OR DIRECT THE VOTE
0 Shares
(iii) SOLE POWER TO DISPOSE OR TO DIRECT THE DISPOSITION OF
1,467,402 Shares
(iv) SHARED POWER TO DISPOSE OR TO DIRECT THE DISPOSITION OF
0 Shares
--------------------------------------------------------------------------------
Schon wieder News.........Anscheinend haben da einige grössere Investoren auch Interesse
Buy Buy.........Strong buy
SCHEDULE 13G/A
UNDER THE SECURITIES EXCHANGE ACT OF 1934
(AMENDMENT NO. 3)*
Interferon Sciences, Inc.
--------------------------------------------------------------------------------
(Name of Issuer)
COMMON STOCK, $.01 PAR VALUE
--------------------------------------------------------------------------------
(Title of Class of Securities)
458903408
--------------------------------------------------------------------------------
(CUSIP Number)
*The remainder of this cover page shall be filled out for a reporting person`s initial filing on this form with respect to the subject class of securities, and for any subsequent amendment containing information which would alter the disclosures provided in a prior cover page.
The information required in the remainder of this cover page shall not be deemed to be "filed" for the purpose of Section 18 of the Securities Exchange Act of 1934 ("Act") or otherwise subject to the liabilities of that section of the Act but shall be subject to all other provisions of the Act (however, see the Notes).
(Continued on following page(s))
--------------------------------------------------------------------------------
Page 1 of 4 Pages
--------------------------------------------------------------------------------
----------------------------- ------------------------------
CUSIP No. 458903408 13G/A Page 2 of 4 Pages
----------------------------- ------------------------------
--------------------------------------------------------------------------------
1. NAMES OF REPORTING PERSON
S.S. OR I.R.S. IDENTIFICATION NO. OF ABOVE PERSON
Celeste Trust Reg.
--------------------------------------------------------------------------------
2. CHECK THE APPROPRIATE BOX IF A MEMBER OF A GROUP:
(a) |_|
(b) |_|
--------------------------------------------------------------------------------
3. SEC USE ONLY
--------------------------------------------------------------------------------
4. CITIZENSHIP OR PLACE OF ORGANIZATION
Liechtenstein
--------------------------------------------------------------------------------
5. SOLE VOTING POWER
NUMBER OF 1,467,402 shares of Common Stock
SHARES --------------------------------------------------------
BENEFICIALLY 6. SHARED VOTING POWER
OWNED BY None
EACH --------------------------------------------------------
REPORTING 7. SOLE DISPOSITIVE POWER
PERSON WITH 1,467,402 shares of Common Stock
--------------------------------------------------------
8. SHARED DISPOSITIVE POWER
None
--------------------------------------------------------------------------------
9. AGGREGATE AMOUNT BENEFICIALLY OWNED BY EACH REPORTING
PERSON
1,467,402 shares of Common Stock
--------------------------------------------------------------------------------
10. CHECK BOX IF THE AGGREGATE AMOUNT IN ROW (9) EXCLUDES
CERTAIN SHARES |_|
--------------------------------------------------------------------------------
11. PERCENT OF CLASS REPRESENTED BY AMOUNT IN ROW 9
7.1%
--------------------------------------------------------------------------------
12. TYPE OF REPORTING PERSON
CO
-------------------------------------------------------------------------------
--------------------------------------------------------------------------------
CUSIP NO. 458903408 PAGE 3 OF 4 PAGES
--- ---
ITEM 1 (a) NAME OF ISSUER: Interferon Sciences, Inc.
ITEM 1 (b) ADDRESS OF ISSUER`S PRINCIPAL EXECUTIVE OFFICES:
783 Jersey Avenue, New Brunswick, NJ 08901
ITEM 2 (a) NAME OF PERSON FILING: Celeste Trust Reg.
ITEM 2 (b) ADDRESS OF PRINCIPAL BUSINESS OFFICE OR, IF NONE, RESIDENCE:
Trevisa-Treuhand-Anstalt, Landstrasse 8, 9496 Furstentums,
Balzers, Liechtenstein
ITEM 2 (c) CITIZENSHIP: Liechtenstein
ITEM 2 (d) TITLE OF CLASS OF SECURITIES: Common Stock, $.01 par value
ITEM 2 (e) CUSIP NUMBER: 458903408
ITEM 3 IF THIS STATEMENT IS FILED PURSUANT TO RULE 13D-1(B) OR
13D-2(B): Not applicable
ITEM 4 OWNERSHIP
(a) AMOUNT BENEFICIALLY OWNED: 1,467,402 Shares of Common Stock
(b) PERCENT OF CLASS: 7.1%
(c) NUMBER OF SHARES AS TO WHICH SUCH PERSON HAS:
(i) SOLE POWER TO VOTE OR DIRECT THE VOTE
1,467,402 Shares
(ii) SHARED POWER TO VOTE OR DIRECT THE VOTE
0 Shares
(iii) SOLE POWER TO DISPOSE OR TO DIRECT THE DISPOSITION OF
1,467,402 Shares
(iv) SHARED POWER TO DISPOSE OR TO DIRECT THE DISPOSITION OF
0 Shares
--------------------------------------------------------------------------------
@all
da hier irgendwie kein Interesse besteht sich zu unterhalten werde ich mich nun -in the Underground- of Interferon begeben.
LINKS , NEWS, und die aktuelle Lage wisst Ihr ja nun zu genüge. Mir ist das irgendwie zu doof zu posten und nichts tut sich.
Wer will : per Postfach
Viel Glück ......
P.S Melde mich später dann wieder wenn ich reich bin
Und nicht vergessen Stichtag.......baaaaaallllddddd
da hier irgendwie kein Interesse besteht sich zu unterhalten werde ich mich nun -in the Underground- of Interferon begeben.
LINKS , NEWS, und die aktuelle Lage wisst Ihr ja nun zu genüge. Mir ist das irgendwie zu doof zu posten und nichts tut sich.
Wer will : per Postfach
Viel Glück ......
P.S Melde mich später dann wieder wenn ich reich bin
Und nicht vergessen Stichtag.......baaaaaallllddddd
Hallo alter Kämpfer!
Ich warte immer noch auf die Ausführung meiner Order
bei 0,06$.
"Leider" scheint nach wie vor niemand verkaufen zu
wollen.
Ich hoffe jedenfalls auf Reichtum
Im Übrigen empfehle ich nochmals DGENQ anzugucken.
Aktuell wieder +70% und ebensowenig Verkaufsdruck
wie IFSC.
Ich sehe gerade Bayern - Real.
Bayern wird verlieren.
gruß von der Isar
schlumpfomat
Ich warte immer noch auf die Ausführung meiner Order
bei 0,06$.
"Leider" scheint nach wie vor niemand verkaufen zu
wollen.
Ich hoffe jedenfalls auf Reichtum
Im Übrigen empfehle ich nochmals DGENQ anzugucken.
Aktuell wieder +70% und ebensowenig Verkaufsdruck
wie IFSC.
Ich sehe gerade Bayern - Real.
Bayern wird verlieren.
gruß von der Isar
schlumpfomat
Warum merkt hier eigentlich keiner was läuft und das was läuft...........
Die Weicheier verkaufen und die , die wissen was läuft kaufen.....
Sagt mal wie kann man nur so........sein
Es wird beschlossen das IFSC das Medi an HEB verkauft.
Falls Ihr aber nicht wissen solltet was das heisst:
Heb hat Kurspotential bis xx Dollar. IFSC bekommt von Heb über 1,x Millionen Aktien....das bedeutet das der Cashwert von IFSC weit über 10 MillDollar liegen wird.
Bei 20 Millionen Shares von IFSC bedeutet das einen 2 stelligen Kurs...ach ja Heb hat bereits alle Schulden von IFSC bezahlt und übernimmt auch die restlichen Kosten was Miete, Strom.....ect.betrifft.
Es kommt aber noch besser: Es wurde ein 3 jähriger Vertrieb des Medikamentes von IFSC durch Heb vereinbart. IFSC bekommt davon 6% vom Netto....und nach 3 Jahren ist das Medi wieder bei IFSC.
Diese Vereinbarung des verkaufs an Heb ist nur 3 Jahre gültig....Hallo ....
ich kann nur sagen : Jetzt oder nie........
IHR WERDET ES BEREUEN
Sagt mal wie kann man nur so........sein
Es wird beschlossen das IFSC das Medi an HEB verkauft.
Falls Ihr aber nicht wissen solltet was das heisst:
Heb hat Kurspotential bis xx Dollar. IFSC bekommt von Heb über 1,x Millionen Aktien....das bedeutet das der Cashwert von IFSC weit über 10 MillDollar liegen wird.
Bei 20 Millionen Shares von IFSC bedeutet das einen 2 stelligen Kurs...ach ja Heb hat bereits alle Schulden von IFSC bezahlt und übernimmt auch die restlichen Kosten was Miete, Strom.....ect.betrifft.
Es kommt aber noch besser: Es wurde ein 3 jähriger Vertrieb des Medikamentes von IFSC durch Heb vereinbart. IFSC bekommt davon 6% vom Netto....und nach 3 Jahren ist das Medi wieder bei IFSC.
Diese Vereinbarung des verkaufs an Heb ist nur 3 Jahre gültig....Hallo ....
ich kann nur sagen : Jetzt oder nie........
IHR WERDET ES BEREUEN
Beitrag zu dieser Diskussion schreiben
Zu dieser Diskussion können keine Beiträge mehr verfasst werden, da der letzte Beitrag vor mehr als zwei Jahren verfasst wurde und die Diskussion daraufhin archiviert wurde.
Bitte wenden Sie sich an feedback@wallstreet-online.de und erfragen Sie die Reaktivierung der Diskussion oder starten Sie eine neue Diskussion.
Meistdiskutiert
Wertpapier | Beiträge | |
---|---|---|
127 | ||
83 | ||
48 | ||
28 | ||
26 | ||
20 | ||
18 | ||
14 | ||
12 | ||
12 |
Wertpapier | Beiträge | |
---|---|---|
11 | ||
9 | ||
9 | ||
9 | ||
8 | ||
8 | ||
7 | ||
7 | ||
6 | ||
6 |